Skip to main content

A Multicenter Randomized Controlled Trial of a Digital Health Intervention for Medication Optimization in Heart Failure: The ENGAGE-HF Trial Outcomes

In brief

Heart failure app raises medication optimization score by 9.7 points

In 134 recently hospitalized patients with reduced or mildly reduced heart function, the app-based program raised the 90-day medication optimization score to 83.7%, versus 74.0% with usual care. More patients received key therapies or reached target doses, but quality-of-life scores did not differ significantly; whether better prescribing leads to lasting benefits or fewer hospitalizations remains unknown.

Journal
Circulation. Heart failure (Q1)
Published
8 November 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Michael P Dorsch, Nisha A Gilotra, Erin M Spaulding, Seth S Martin, Henry Zhao, Grant A Wilson, et al.
PMID
42999997
DOI
10.1161/CIRCHEARTFAILURE.126.015192

Why clinicians should know about it

  • Picked for Family Practice (top studies of the week, 15 November 2026): Heart-failure medication optimization after hospital discharge

Abstract

Background: Despite clear evidence that guideline-directed medical therapy (GDMT) significantly reduces mortality and hospitalizations in patients with heart failure (HF) with reduced and mildly reduced ejection fraction, real-world implementation remains suboptimal. Digital health interventions may promote GDMT titration after hospital discharge. Methods: The ENGAGE-HF trial was a multicenter, two-arm, open-label, randomized controlled trial across three academic centers, funded by the AHA Strategically Focused Research Network (SFRN) for Health Technology and Innovation. Patients recently hospitalized with HF, with or without a primary hospital diagnosis of HF, and LVEF <50% receiving suboptimal GDMT were randomized 1:1 to either the ENGAGE-HF app or usual care for 90 days. The ENGAGE-HF intervention consisted of a patient-facing mobile app and a clinician dashboard overseen by study coordinators. The primary outcome was the Medication Optimization Score (MOS, scale 0-100%) at 90 days. Secondary outcomes were individual GDMT therapies and the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score at 90 days. Results: A total of 134 participants were randomized. At 90 days, the adjusted MOS was significantly higher in the ENGAGE-HF group compared to the control group (83.7% vs. 74.0%, p = 0.010). Results remained consistent across multiple sensitivity analyses. Overall prescribing prevalence increased more in the ENGAGE-HF group for MRAs (+15.9 vs. +2.5 percentage points) and SGLT2 inhibitors (+10.9 vs. +2.5 percentage points). Furthermore, the ENGAGE-HF group demonstrated greater increases in achieving target doses for ARNI (+18.8% vs. +6.3%) and beta-blockers (+8.5% vs. +0.6%). KCCQ-23 CSS at 90 days was 75.2 (SE 2.6) in the intervention group versus 72.2 (SE 2.6) in the control group (between-group p = 0.40). Conclusions: ENGAGE-HF, a digital health intervention that integrates remote monitoring, patient engagement, and clinical decision support, significantly improved GDMT optimization at 90 days compared with usual care among patients with HF. Registration: URL: https://clinicaltrials.gov Unique Identifier: NCT06750549.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.